F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis of pancreatic tumors

详细信息    查看全文

• 作者：Masato Yoshioka ; Hiroshi Uchinami ; Go Watanabe ; Tsutomu Sato…
• 关键词：FDG ; PET ; SUV ; Cut ; off ; IPMN ; Non ; ductal pancreatic cancer
• 刊名：SpringerPlus
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：4
• 期：1
• 全文大小：1012KB
• 参考文献：Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, Schumpelick V, Mittermayer C, B眉ll U (1994) F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192:79鈥?6CrossRef
  Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC (2013) Simultaneous 65Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol 48:273鈥?79CrossRef
  Berberat P, Freiss H, Kashiwagi M, Berger HG, B眉chler MW (1999) Diagnosis and staging of pancreatic cancer by positron emission tomography. World J Surg 23:882鈥?87CrossRef
  Brom M, Oyen WJG, Joosten L, Gotthardt M, Boerman OC (2010) 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 37:1345鈥?355CrossRef
  Delbeke D (1999) Oncological applications of FDG-PET imaging. J Nucl Med 40:1706鈥?715
  Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, Shyr Y, Leach SD (1999) Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 40:1784鈥?791
  Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, Townsend DW, Berland LL, Parker JA, Hubner K, Stabin MG, Zubal G, Kachelriess M, Cronin V, Holbrook S (2006) Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 47:885鈥?95
  Eriksson O, Velikyan I, Selvaraju RK, Kandeel F, Johansson L, Antoni G, Eriksson B, S枚rensen J, Korsgren O (2014) Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. J Clin Endocrinol Metab 99:1519鈥?524CrossRef
  Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508鈥?18CrossRef
  Herrmann K, Erkan M, Dobritz M, Schuster T, Siveke JT, Beer AJ, Wester HJ, Schmid RM, Friess H, Schwaiger M, Kleeff J, Buck AK (2012) Comparison of 3鈥?deoxy-3鈥?[18F] fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tunours. Eur J Nucl Med Mol Imaging 39:846鈥?51CrossRef
  Hong HS, Yun M, Cho A, Choi JY, Kim MJ, Kim KW, Choi YJ, Lee JD (2010) The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm. Clin Nucl Med 35:776鈥?79CrossRef
  Imdahl A, Nitzsche E, Krautmann F, H枚gerle S, Boos S, Einert A, Sontheimer J, Farthmann EH (1999) Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 86:194鈥?99CrossRef
  Inokuma T, Tamaki N, Torizuka T, Fujita T, Magata Y, Yonekura Y, Ohshio G, Imamura M, Konishi J (1995) Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med 36:229鈥?35
  Ishizu K, Sadato N, Yonekura Y, Nishizawa S, Magata Y, Tamaki N, Tsuchida T, Okazawa H, Tanaka F, Miyatake S, Ishikawa M, Kikuchi H, Konishi J (1994) Enhanced detection of brain tumors by [18F]fluorodeoxyglucose PET with glucose loading. J Comput Assist Tomogr 18:12鈥?5CrossRef
  Jansson T, Westlin JE, Ahlstrom H, Lija A, Langstrom B, Bergh J (1995) Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 13:1470鈥?477
  Kamisawa T, Takum K, Anjiki H, Egawa N, Kurata M, Honda G, Tsuruta K (2010) FDG-PET/CT findings of autoimmune pancreatitis. Hepatogastroenterology 57:447鈥?50
  Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, Iwata R, Ido T (1990) Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 31:1927鈥?932
  Lewis JS, Srinivasan A, Schmidt MA, Anderson CJ (1999) In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake. Nucl Med Biol 26:267鈥?73CrossRef
  Mansour JC, Schwartz L, Pandit-Taskar N, D鈥橝ngelica M, Fong Y, Larson SM, Brennan MF, Allen PJ (2006) The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg 10:1354鈥?360CrossRef
  Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Imamura M, Konishi J (1999) Contribution of PET in the detection of liver metastasis from pancreatic tumours. Clin Radiol 54:248鈥?52CrossRef
  Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, Hosotani R, Imamura M, Konishi J (2000) Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 89:2547鈥?554CrossRef
  Nitzsche EU, Hoegerle S, Mix M, Brink I, Otte A, Moser E, Imdahl A (2002) Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nuc Med Mol Imaging 29:237鈥?42CrossRef
  Pedrazzoli S, Sperti C, Pasquali C, Bissoli S, Chierichetti F (2011) Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 254:971鈥?76CrossRef
  Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pederson PL (1996) Glucose metabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res 56:2468鈥?471
  Sadato N, Tsuchida T, Nakaumra S, Waki A, Uematsu H, Takahashi N, Hayashi N, Yonekura Y, Ishii Y (1998) Non-invasive estimation of the net influx constant using the standardized uptake value for quantification of FDG uptake of tumours. Eur J Nucl Med 25:559鈥?64CrossRef
  Sperti C, Pasquali C, Chierichetti F, Liessi G, Ferlin G, Pedrazzoli S (2001) Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg 234:675鈥?80CrossRef
  Sperti C, Pasquali C, Decet G, Chierichetti F, Liessi G, Padrazzoli S (2005) F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg 9:22鈥?9CrossRef
  Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S (2007) 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 246:932鈥?39CrossRef
  Takanami K, Hiraide T, Tsuda M, Nakamura Y, Kaneta T, Takase K, Fukuda H, Takahashi S (2011) Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules. Ann Nucl Med 25:501鈥?10CrossRef
  Tann M, Sandrasegaran K, Jennings SG, Skandarajah A, Mchenry L, Schmidt CM (2007) Positron-emission tomography and computed tomography of cystic pancreatic masses. Clin Radiol 62:745鈥?51CrossRef
  Tomimaru Y, Takeda Y, Tatsumi M, Kim T, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Kitagawa T, Nagano H, Umeshita K, Wakasa K, Doki Y, Mori M (2010) Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Oncol Rep 24:613鈥?20
  Wahl RL, Cody RL, Hutchins GD, Mudgett EE (1991) Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy D-glucose. Radiology 179:765鈥?70CrossRef
  Wild D, Wicki A, Mansi R, B茅h茅 M, Keil B, Bernhardt P, Christofori G, Ell PJ, M盲cke HR (2010) Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 51:1059鈥?067CrossRef
  Yoshioka M, Sato T, Furuya T, Shibata S, Andoh H, Asanuma Y, Hatazawa J, Shimosegawa E, Koyama K, Yamamoto Y (2004) Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer. J Gastroenterol 39:50鈥?5CrossRef
  
• 作者单位：Masato Yoshioka (1)
  Hiroshi Uchinami (1)
  Go Watanabe (1)
  Tsutomu Sato (2)
  Satoshi Shibata (3)
  Makoto Kume (4)
  Koichi Ishiyama (5)
  Satoshi Takahashi (5)
  Manabu Hashimoto (5)
  Yuzo Yamamoto (1)
  
  1. Department of Gastroenterological Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan
  2. Department of Surgery, Akita City Hospital, Akita, 010-0933, Japan
  3. Department of Surgery, Honjo Daiichi Hospital, Honjo, Akita, 015-8567, Japan
  4. Department of Surgery, Murakami Memorial Hospital, Asahi University, Gifu, 500-8523, Japan
  5. Department of Radiology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan
  
• 刊物类别：Science, general;
• 刊物主题：Science, general;
• 出版者：Springer International Publishing
• ISSN：2193-1801

文摘

Positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose (FDG-PET) has been proven useful for differentiating pancreatic ductal cancer from mass-forming chronic pancreatitis. However, there are particular pancreatic tumors having various grades of malignancy such as intraductal papillary mucinous neoplasm (IPMN) or pancreatic neuroendocrine tumor. We examined whether the cut-off value of maximum standardized uptake value (SUV_max) determined by pancreatic ductal cancers is also applicable for other pancreatic tumors. One hundred thirty six patients with pancreatic tumors underwent FDG-PET imaging. We first analyzed the cut-off value to differentiate pancreatic ductal cancers from mass-forming chronic pancreatitis. Secondly, we determined the cut-off value between malignant IPMN and benign IPMN. Thirdly, we computed a cut-off value between malignant pancreatic tumors and benign tumors irrespective of tumor type. The optimal cut-off value to differentiate ductal cancers from mass-forming chronic pancreatitis was 2.5. The optimal cut-off value for differentiating malignant IPMN from benign IPMN was also 2.5, similar to that of reported studies. In all types of pancreatic tumors, the cut-off value was also 2.5. The accuracy for detecting malignancy was 93.4% for all tumors. In the FDG-PET study for pancreatic tumors, an SUV_max of 2.5 would be justified as a cut-off value to differentiate malignant lesions. Keywords FDG-PET SUV Cut-off IPMN Non-ductal pancreatic cancer